Accéder au contenu
Merck

Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes.

Antimicrobial agents and chemotherapy (2001-06-16)
D Sereno, P Holzmuller, I Mangot, G Cuny, A Ouaissi, J L Lemesre
RÉSUMÉ

The basic treatment of leishmaniasis consists in the administration of pentavalent antimonials. The mechanisms that contribute to pentavalent antimonial toxicity against the intracellular stage of the parasite (i.e., amastigote) are still unknown. In this study, the combined use of several techniques including DNA fragmentation assay and in situ and cytofluorometry terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling methods and YOPRO-1 staining allowed us to demonstrate that potassium antimonyl tartrate, an Sb(III)-containing drug, was able to induce cell death associated with DNA fragmentation in axenic amastigotes of Leishmania infantum at low concentrations (10 microg/ml). This observation was in close correlation with the toxicity of Sb(III) species against axenic amastigotes (50% inhibitory concentration of 4.75 microg/ml). Despite some similarities to apoptosis, nuclease activation was not a consequence of caspase-1, caspase-3, calpain, cysteine protease, or proteasome activation. Altogether, our results demonstrate that the antileishmanial toxicity of Sb(III) antimonials is associated with parasite oligonucleosomal DNA fragmentation, indicative of the occurrence of late events in the overall process of apoptosis. The elucidation of the biochemical pathways leading to cell death could allow the isolation of new therapeutic targets.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Potassium antimonyl tartrate trihydrate, puriss., meets analytical specification of USP, 99.0-103.0%, powder
Sigma-Aldrich
Potassium antimonyl tartrate trihydrate, purum p.a., 99.0-103% (RT)